Alimentiv Inc.
Clinical trials sponsored by Alimentiv Inc., explained in plain language.
-
Crohn's patients in remission may ditch daily pills, study hints
Disease control OngoingThis study looks at whether people with Crohn's disease who are in remission can safely stop taking aminosalicylate (5-ASA) medication without their condition getting worse. About 334 participants will either continue or stop their 5-ASA therapy and be followed for 2 years to see…
Phase: PHASE4 • Sponsor: Alimentiv Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New study aims to pinpoint fastest Crohn's symptom relief
Knowledge-focused OngoingThis study follows 300 adults with Crohn's disease who are starting standard treatments like vedolizumab or IL-23 blockers. Researchers will track how quickly patients feel improvements in pain, fatigue, and daily functioning using simple questionnaires. The goal is to better und…
Sponsor: Alimentiv Inc. • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Scientists track drug behavior in severe colitis patients
Knowledge-focused OngoingThis study looks at how the drug infliximab behaves in the body of people hospitalized with severe ulcerative colitis. Researchers measure drug levels in blood, stool, and colon tissue, along with changes in proteins and genes. The goal is to better understand how the drug works,…
Sponsor: Alimentiv Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Ulcerative colitis study aims to pinpoint the perfect treatment goal
Knowledge-focused OngoingThis study looks at 672 people with active ulcerative colitis to find the best treatment target. Participants are split into three groups: one aiming for symptom relief only, another for symptom plus endoscopic healing, and a third for symptom, endoscopic, and microscopic healing…
Phase: PHASE4 • Sponsor: Alimentiv Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC